pulmonaryfibrosisnews12d
MTX-463 expected to enter Phase 2 testing in IPF in first half of 2025
Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.
pulmonaryfibrosisnews1d
When we share our experiences with IPF, it’s not a competition
Everyone's IPF journey is unique, columnist Sam Kirton says, but that does not mean our experiences should become a competition.
pulmonaryfibrosisnews5d
Study uncovers why PF after severe COVID-19 doesn’t progress
An imbalance in gene activity in two types of immune cells explains why lung fibrosis after a severe COVID-19 infection doesn ...
pulmonaryfibrosisnews8d
Dealing with grief is unique to each of us in the PF community
Columnist Sam Kirton says that at his age, and as someone with pulmonary fibrosis, he's had much experience dealing with grief.